FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns applications of compositions formulated as follows 
or its salt, solvate or prodrug of medical agent for treatment or prevention of disease state mediated by glucokinase (GLK). Besides, given invention concerns new group of composition formulated as (I) and to method of specified compositions production. The invention enables to widen range of agents used for treatment or prevention of disease conditions mediated by glucokinase (GLK) where each of R1, R2, R3, n and m has values specified in the description.
EFFECT: increased efficiency.
19 cl, 51 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2014 |
|
RU2680100C9 |
| DIPHENYLAZETIDINONE DERIVATIVES, METHODS FOR OBTAINING SAME, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS OF SAID DERIVATIVES AND APPLICATION THEREOF IN CHOLESTEROL ABSORPTION INHIBITION | 2003 |
|
RU2333199C2 |
| NEW COMPOUNDS FOR MODULATION OF CELLULAR PROLIFERATION | 2001 |
|
RU2277531C9 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
| QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USED AS MUSCARINIC RECEPTOR ANTAGONISTS | 2008 |
|
RU2452728C2 |
| COMPOUNDS AND COMPOSITIONS AS CANAL ACTIVATING PROTEASE INHIBITORS | 2007 |
|
RU2419626C2 |
| NEW P2X7 RECEPTOR ANTAGONISTS, METHOD OF OBTAINING THEM, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE, BASED ON ANTAGONISTS | 2004 |
|
RU2347778C2 |
| DPP-IV INHIBITORS | 2005 |
|
RU2345067C2 |
| N-PYRAZINYLPHENYLSULFONAMIDES AND THEIR USING IN TREATMENT OF CHEMOKINE-MEDIATED DISEASES | 2003 |
|
RU2312105C9 |
| PYRROLOTRIAZINE ANILINE DERIVATIVES EFFECTIVE AS KINASE INHIBITORS | 2003 |
|
RU2375363C2 |
